NewCardio, Inc., through its patent-pending, innovative technology, is poised to transform the landscape of electrocardiography (ECG). The company has developed, and is currently working to commercialize, a three-dimensional ECG platform that stands to seriously improve upon traditional methods.
In addition to a dramatic increase in diagnostic accuracy, the NewCardio 3D ECG works faster, and with greater cost-effectiveness than the standard 12 lead ECG. NewCardio’s advanced systems aid not only in the diagnosis of heart disorders, but also in clinical pharmaceutical trials with respect to the evaluation of a drug’s potential cardiac toxicity. This should allow the company to become a force to be reckoned with, operating within a billion-dollar market sector. Validation studies have already commenced at Harvard University Medical School, and have produced some positive results.
While the trials continue, NewCardio’s revenue mainly comes from its lead product – the QTinno™ software suite. This platform provides automated analysis of difficult-to-read electrocardiograms. For the first time, human beings need not be relied upon for the statistical evaluation of a drug’s potential effects on the heart. Overall, NewCardio, Inc. uses revolutionary thinking and technologically sound ideas to approach ECG methodology in a new and exciting way.
Let us hear your thoughts below:
